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ABSTRACT
Understanding the coordination between humoral and cellular immune responses may be the key to developing protective vac-
cines, and because genetic studies of long-term HIV-1 nonprogressors have associated specific HLA-B alleles with spontaneous
control of viral replication, this subject group presents an opportunity to investigate relationships between arms of the adaptive
immune system. Given evidence suggesting that cellular immunity may play a role in viral suppression, we sought to determine
whether and how the humoral immune response might vary among controllers. Significantly, Fc-mediated antibody effector
functions have likewise been associated with durable viral control. In this study, we compared the effector function and biophys-
ical features of HIV-specific antibodies in a cohort of controllers with and without protective HLA-B alleles in order to investi-
gate whether there was evidence for multiple paths to HIV-1 control, or whether cellular and humoral arms of immunity might
exhibit coordinated profiles. However, with the exception of IgG2 antibodies to gp41, HLA status was not associated with diver-
gent humoral responses. This finding did not result from uniform antibody responses across subjects, as controllers could be
regrouped according to strong differences in their HIV-specific antibody subclass specificity profiles. These divergent antibody
profiles were further associated with significant differences in nonneutralizing antibody effector function, with levels of HIV-
specific IgG1 acting as the major distinguishing factor. Thus, while HLA background among controllers was associated with
minimal differences in humoral function, antibody subclass and specificity profiles were associated with divergent effector func-
tion, suggesting that these features could be used to make functional predictions. Because these nonneutralizing antibody activi-
ties have been associated with spontaneous viral control, reduced viral load, and nonprogression in infected subjects and protec-
tion in vaccinated subjects, understanding the specific features of IgGs with potentiated effector function may be critical to
vaccine and therapeutic antibody development.
IMPORTANCE
In this study, we investigated whether the humoral and cellular arms of adaptive immunity exhibit coordinated or compensatory
activity by studying the antibody response among HIV-1 controllers with different genetic backgrounds.
Elite controllers (ECs) are individuals able to spontaneouslysuppress viral replication to below the limit of detection (50
viral RNA copies/ml of blood), and as such, they represent a
promising opportunity to study protective immune responses to
human immunodeficiency virus (HIV) infection (1). While the
mechanisms behind control of viral replication remain unclear,
genetic studies of ECs have pointed to a CD8 T cell-mediated
mechanism of control. A genome-wide association study (GWAS)
revealed associations between HLA-B alleles and control, with the
HLA-B*5701 allele providing the strongest independent associa-
tion (2, 3) and other alleles demonstrating association in an addi-
tive manner (4). Additional evidence implicates altered major his-
tocompatibility complex (MHC) class I peptide binding resulting
in superior viral recognition; specific amino acid residues within
the MHC class I peptide-binding groove were associated with con-
trol (5), and an in silico model of thymic selection with the HLA-
B*5701 allele resulted in a higher proportion of naive T cells able
to recognize viral epitopes and cross-react with mutants of tar-
geted epitopes (6). Other studies have also shown evidence for a
CD8 T cell-based mechanism of control at the cellular level (7,
8). Together, this evidence suggests differential peptide presenta-
tion as a possible mechanism of viral control associated with
HLA-B alleles: presentation of viral peptides that promote supe-
rior CD8 T cell activation or that are crucial to viral fitness may
ultimately result in reduced viral immune evasion and effective
suppression.
Although there is compelling evidence for a T cell-mediated
mechanism of control, it does not paint a comprehensive picture:
while protective HLA alleles B57 and B27 are highly enriched among
ECs (observed in 44 and 15%, respectively), the majority of ECs do
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not carry a protective HLA allele, many progressors possess these
alleles, and immune responses in ECs are highly heterogeneous and
may involve multiple mechanisms (7). Spontaneous control of HIV
infection is thus complex: differential T cell activation may alterna-
tively supplant a weaker or drive a stronger B cell response. While
significant differences in the humoral immune response between
controllers and progressors have been noted (9–15), the role that
humoral immunity may play in viral control in the context of protec-
tive HLA alleles is incompletely resolved (16, 17).
Notably, antibodies can function as molecular beacons to re-
cruit effector cells of the innate immune response, such as NK
cells, macrophages, and dendritic cells. These effector functions
include antibody-dependent cellular cytotoxicity (ADCC), anti-
body-dependent cellular phagocytosis (ADCP), and antibody-de-
pendent complement-dependent cytotoxicity (ADCDC). The
sum of these and other functions can be measured more generally
as antibody-dependent cellular viral inhibition (ADCVI), and a
number of studies have suggested that these extraneutralizing ef-
fector functions of antibodies play a role in an effective immune
response to HIV (summarized in reference 18). In both humans
and macaques, ADCC activity has correlated with delayed pro-
gression to AIDS (12, 13, 19, 20), and ADCVI has been reported in
early stages of simian immunodeficiency virus (SIV) infection,
coincident with the appearance of anti-gp140 antibodies. Viruses
that had mutated to escape neutralization remained susceptible to
ADCVI during later infection, and ADCVI was correlated with
control of viral replication, showing that at least in this model,
ADCVI played a substantial role in a protective immune response
(21). Furthermore, in a French cohort, ADCC antibodies were
detected at higher levels in nonprogressors than in viremic pa-
tients. Notably, ADCC responses were present in some patients
with low CD8 T cell activity, suggesting ADCC as an alternative
route to control of viral replication (15). These associations with
nonprogressive infection may mirror protective immune re-
sponses in the setting of vaccination, as in monkeys, vaccine-elic-
ited antibodies with ADCC activity have correlated with protec-
tion or reduced viral loads (22–24), and in humans, antibodies
with ADCC or ADCVI activity correlated with reduced risk of
infection in the VAX004 trial and were readily induced in the
RV144 trial, where in the absence of IgA, they correlated with
reduced risk of infection (25–27).
Given both cellular and humoral associations with control of
viral replication in ECs, we were motivated to investigate a possi-
ble relationship between these arms of adaptive immunity. More
specifically, we sought to determine if the presence or absence of a
protective HLA allele was associated with divergent humoral re-
sponses, supporting either the hypothesis that there are multiple
paths to HIV type 1 (HIV-1) control, and that humoral immunity
may be potentiated in controllers without protective HLA alleles,
or the hypothesis that the humoral and cellular arms of immunity
may be coordinately regulated in ECs. Our study was based on a
cohort of 40 ECs, 20 with and 20 without a protective HLA allele.
To probe the humoral response, we assayed antibody effector
functions, including ADCC and ADCP, in cellular assays. Because
these extraneutralizing effector functions are dependent on the
interactions between the antibody’s Fc region and the Fc recep-
tors on effector cells, and vary between different IgG subclasses
(IgG1, IgG2, IgG3 and IgG4), Fc glycoforms, and among the set of
Fc receptors (28), we utilized a multiplexed assay to simultane-
ously assess antibody subclass and antigen specificity and further
characterized bulk plasma IgG binding to FcR and lectins.
With the exception of IgG2 responses to gp41, we saw that the
presence or absence of a protective HLA allele was not associated
with divergent antibody responses among controllers. However,
regardless of HLA status, using antibody subclass specificity data,
subjects could be classified into two groups with distinct humoral
profiles. Whereas the HLA-defined groups exhibited no differ-
ences in antibody effector functions, the groups defined by fea-
tures of their HIV-specific antibody responses, hereafter called
array-defined groups, exhibited differential ADCP and ADCC ac-
tivities, mannose-binding lectin (MBL) binding, and FcR2A
binding. Array-defined groups were primarily differentiated by
the magnitude of the IgG1 response to HIV antigens. Thus, while
the HLA background provided limited impact on humoral func-
tion, antibody subclass and specificity profiles were associated
with divergent effector function. The ability of the antibody sub-
class specificity array and naive clustering methods to predict ef-
fector function both represents a biophysical means to predict
activity in cell-based assays and points toward specific features of
the humoral immune response as associated with these protective
activities; it may therefore provide valuable insights into Fc-me-
diated antibody activities and immune control.
MATERIALS AND METHODS
Subject antibodies. ECs were chosen from a cohort of HIV-1-infected
individuals that has been described previously (7). ECs were defined as
subjects with plasma HIV RNA levels of 50 or 75 copies/ml based on
a minimum of three determinations of plasma HIV RNA spanning at least
a 12-month period in the absence of antiretroviral therapy. For compar-
ison, 20 ECs containing protective HLA alleles, defined as B5701, B5703,
or B2705, and 20 ECs without protective HLA alleles were selected at
random. Subject characteristics are presented in Table S1 in the supple-
mental material. IgG was purified from plasma samples using the Melon
Gel IgG spin purification kit (Thermo Scientific; 45206). The study was
reviewed and approved by the Massachusetts General Hospital Institu-
tional Review Board, and each subject gave written informed consent.
Cellular assays. ADCP activity was determined using a flow cytomet-
ric assay that measures the uptake of fluorescent gp120-coated beads by
monocytic THP-1 cells in the presence of subject antibody. The antibody-
dependent phagocytosis assay was performed as previously described,
with subject antibodies tested at a concentration of 6.25 g/ml (29, 30).
ADCC activity was characterized using the rapid fluorometric ADCC
(RFADCC) assay with NK cells as effectors, as previously described (31). A
ratio of effectors to target cells of 10:1 was used, and subject antibodies
were tested at a concentration of 50 g/ml. HIV immunoglobulin (HIV-
IG; obtained from NABI and NHLBI, catalog number 3957; NIH AIDS
Reagent Program, Division of AIDS, NIAID, NIH) and pooled human
IgG (HuIgG) from HIV-negative donors (I2511; Sigma) were used as
positive and negative controls. Both functional assays exhibit high
reproducibility (r  0.85) and coefficients of variation (CV) in the
range of 5 to 15%.
Bulk and HIV-specific IgG isotype detection. Purified IgG samples
were characterized for their bulk IgG and bulk IgG1, IgG2, IgG3, and IgG4
subtypes using a Milliplex MAP human immunoglobulin isotype kit
(HGAM-301; Millipore) as recommended by the manufacturer (CV 
12%).
A customized multivariate Luminex assay was utilized to characterize
the subclass of HIV-specific antibodies to gp120, gp140, gp41, and p24
(IT-001-0027p, IT-001-0021p, and IT-001-005p IT-001-017p; Immune-
Technology Corp.), as previously described (32). Briefly, antigens were
covalently conjugated to microspheres coded with internal fluorescent
dyes, allowing for multiplexing. Prepared microspheres were incubated
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with subjects’ plasma IgG, resulting in affinity purification of HIV-specific
IgG. After washing, microspheres were incubated with phycoerythrin
(PE) detection antibodies, specific for IgG subclass type. Antigen specific-
ity (microsphere identification [ID]) and subclass (PE signal) data were
acquired on a FlexMap 3D Luminex cytometer. Background signal, de-
fined as the fluorescence signal of microspheres and PE detection anti-
body in the absence of sample, was subtracted from the mean fluorescence
intensity (MFI) for each measurement, and replicate samples exhibited
coefficients of variation of less than 10%. HIV-IG and pooled HuIgG from
HIV-negative donors were used as positive and negative controls.
FcR enzyme-linked immunosorbent assays (ELISAs). Following
dilution in phosphate-buffered saline (PBS), His-tagged Fc receptors
(recombinant human Fc RI/CD64, RIIA/CD32a, RIIB/C [CD32b/c], or
RIIIA/CD16a; R&D Systems) were immobilized on nickel-nitrilotriacetic
acid (Ni-NTA) HisSorb plates (Qiagen) at 0.5 g/well overnight at 4°C.
Plates were washed three times with PBS-Tween (PBST) and blocked with
100 l/well of 1% bovine serum albumin (BSA) in PBS for 2 h at room
temperature. Subsequent incubations were performed at room tempera-
ture, and washes were performed between steps as described above. Puri-
fied IgG samples were added at 100 g/ml in 3-fold serial dilutions and
incubated for 1 h before washing. Then, 2 g/ml of horseradish peroxi-
dase (HRP)-conjugated secondary detection antibody with the Fc domain
removed [anti-HuIgG () antibody F(ab=)2 fragment, HRP labeled; KPL]
was added at 100 l/well and incubated for 1 h before washing. Signal was
developed by adding 50 l/well of 0.04% o-phenylenediamine dihydro-
chloride (OPD; Sigma) diluted in 0.05 M phosphate citrate buffer, pH 5.0,
and 30% H2O2 (Sigma). The reaction was quenched with 50 l/well of 2.5
N H2SO4, and the optical density (OD) was read at 492 nm with a 650-nm
reference wavelength on a Sunrise microplate absorbance reader (Tecan,
Switzerland, with Magellan, version 6.5, software). Native and deglycosylated
human IgG and a panel of Fc domain point mutated variants of the
broadly neutralizing antibody b12 were used as controls (33), kindly pro-
vided by Dennis Burton. In replicated samples, coefficients of variation
did not exceed 20%.
Lectin ELISAs. The mannose-binding lectin (MBL) and Aleuria au-
rantia lectin (AAL) ELISAs for measuring binding to mannose and fucose
residues on purified patient IgGs were modified from a previously de-
scribed method (34). Purified IgG samples were added at 30 g/ml in
3-fold serial dilutions with 80 l/well on 96-well plates (Maxisorp; Nunc,
Thermo Scientific). Plates were incubated overnight at 4°C and then
washed six times with PBST and blocked with 1% BSA in PBS at 250
l/well for 2 h at room temperature. For MBL assays, the IgG-coated
plates were first acid treated with 0.1 M Gly HCl, pH 2.0, and 0.15 M NaCl
at 100 l/well for 1 h at 37°C and then washed and reblocked for 1 h at
37°C. Biotinylated MBL (10405-H07H [Sino Biological] and 21327
[Thermo Scientific]) or biotinylated AAL (B-1395; Vector Laboratories)
was dissolved in a Ca2 buffer (20 mM Tris-HCl [pH 7.4], 0.15 M NaCl,
2 mM CaCl2, 0.1% BSA, 0.1% Tween 20) and added at 2 g/ml with 100
l/well and incubated for 2 h at room temperature before washing. HRP-
streptavidin (SA-5004; Vector Laboratories) diluted in PBS was added at 2
g/ml with 100 l/well before washing. Substrate development and OD
readings were performed as described above. Native and deglycosylated
human IgG served as positive and negative controls. In replicated samples,
coefficients of variation did not exceed 20%.
Statistical analyses. Comparative analyses of antibody properties be-
tween patient groups were performed using unpaired two-tailed t tests
with 95% confidence intervals and GraphPad Prism software. Because
posttest corrections can introduce errors and rest on debatable assump-
tions, P values below 0.05 are reported alongside the corresponding Bon-
ferroni adjusted significance threshold () to allow for correction based
on family-wise errors associated with multiple comparisons. Correlation
analyses were also performed in GraphPad Prism. Pearson correlation
coefficients were calculated with two-tailed P values with 95% confidence
intervals.
Clustering analysis was performed using the R software package.
Antibody features were scaled and normalized according to their stan-
dard deviation (SD) from the mean, and truncated at 6 SDs. Pearson
correlation coefficients were calculated for HIV-specific IgG isotype
measurements between subjects. Subjects were then clustered using
1 	 r dissimilarity and the Ward Linkage algorithm. The function
heatmap.2 in the R gplots library was used to hierarchically cluster and
visualize the array, grouping and reordering subjects and antibody
features by similarity.
RESULTS
Protective HLA alleles are not associated with divergent hu-
moral profiles. To determine whether ECs with or without pro-
tective HLA alleles have characteristically different HIV-specific
antibody responses, we measured a variety of antibody properties,
including levels of IgG1 to -4 in plasma, IgG galactosylation and
fucosylation levels, FcR binding, antibody-dependent cellular
phagocytosis (ADCP) activity, and antibody-dependent cellular
cytotoxicity (ADCC) activity, as listed in Table S2 in the supple-
mental material. We also determined the subclass composition of
HIV-specific antibodies recognizing gp120, gp41, gp140, and
p24 using a customized microsphere array. Unpaired t test
analyses of antibody properties between HLA-defined groups
revealed limited differences in these measurements (see Fig. S1
to S3 in the supplemental material). Though there was substan-
tial variation among subjects in all assays, only gp41-specific
IgG2 differed between HLA-defined patient groups (P 
 0.03)
(Fig. 1). Though complemented by trends toward increased
levels of IgG2 to other HIV antigens among controllers with
protective HLA-B alleles (see Fig. S1 in the supplemental ma-
terial), in the absence of posttest correction, a statistically weak
difference such as this may be expected as an artifact of multi-
ple comparisons. Indeed, given the number of comparisons
made, Bonferroni correction yields an adjusted significance
threshold () of 0.0018, which is unmet. Thus, among this set
of 28 antibody assays, the presence or absence of a protective
HLA allele was not associated with remarkably divergent anti-
body responses, and the hypothesis that humoral immunity
may be potentiated in subjects according to the absence or
presence of protective HLA alleles was not supported.
IgG subclass specificity profiles define new subject groups.
Given the variability in antibody features and functions observed
between subjects, we next asked if HIV-specific antibody signa-
tures could stratify controllers regardless of HLA status. To ap-
proach this question, we considered only the antigen-specific IgG
FIG 1 IgG2 responses to gp41. A comparison of antibody properties between
elite controllers with (P) and without (NP) protective HLA-B alleles revealed
only a significant difference in IgG2 antibodies against gp41 (P 
 0.03, uncor-
rected; significance threshold of 0.0018 following Bonferroni correction is un-
met). All other antibody properties tested (n 
 27) showed no significant
differences between these HLA-defined groups.
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subclass measurements (n 
 16, IgG1 to -4 specific to gp120,
gp41, gp140, and p24), as measured by the microsphere array.
Using this data, we calculated Pearson correlation coefficients be-
tween subjects, who were then clustered using Ward linkage. Clus-
tering using array data revealed two new and well-defined groups
(designated H and L), which were unrelated to the groups defined
by HLA status (Fig. 2).
Array-defined groups exhibit differential functional activity.
Unpaired t test analysis of antibody properties and function be-
tween array-defined groups (designated H and L) resulted in sig-
nificant differences in both ADCP activity (Fig. 3A) (P 
 0.0047)
and ADCC activity (Fig. 3B) (P 
 0.0183). Furthermore, subjects
in array-defined groups differed with respect to MBL binding of
plasma IgG (Fig. 3C) (P 
 0.0093), suggesting differential anti-
body galactosylation. Similarly, differential binding to FcR2A
was observed (Fig. 3D) (P 
 0.044), consistent with the variation
in phagocytic activity observed. However, the differences in
RFADCC and FcR2A do not meet the significance threshold of
0.0125 following Bonferroni correction. To reconfirm that these
differences were unique to the array-defined groups and not pres-
ent in the HLA-defined groups, comparisons of the same mea-
surements between HLA-defined subject groups (designated P
and NP) were done, and they did not result in any significant
differences (Fig. 3E to H).
Array-defined groups are distinguished by antigen-specific
IgG1 levels. To give better resolution with respect to the antibody
characteristics that distinguished the array-defined groups, we ex-
amined the subjects’ antibody signatures more closely. The corre-
lation matrix analysis (Fig. 2) compressed the 16 antibody signa-
ture data points into single correlation coefficients. Therefore, we
also took an alternative clustering approach that grouped subjects
and antibody properties based on individual antigen subclass
measurements (n 
 16, IgG1 to -4 specific to gp120, gp41, gp140,
and p24). Each antibody feature was centered and scaled accord-
FIG 2 Antibody subclass specificity correlation matrix defines new subject clusters. Correlations between subjects were calculated based on the 16 antibody
subclass specificity features measured on the customized microsphere array. Clustering patients according to their Pearson correlation coefficients, performed by
Ward linkage, revealed two well-differentiated groups of subjects marked by the two branches of the dendrogram (labeled H and L). Subjects with (p) or without
(np) protective alleles were evenly distributed between branches.
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ing to standard deviations from the mean value across all sub-
jects. Features and subjects were then clustered according to
the similarity of their antibody signatures, resulting in a heat
map in which both similar features and similar subjects are
grouped (Fig. 4A). The most striking structural feature of the
heat map clustering was the division of subjects based on anti-
gen-specific IgG1 levels. Subjects were split into two groups, as
represented by the two branches of the dendrogram on the
vertical axis, and these groups were largely structured by high
(red) or low (blue) HIV-specific IgG1 levels. Though they were
not identical, there was excellent agreement between the sub-
ject structure of the correlation matrix (Fig. 2) and heat map
(Fig. 4A), suggesting that the correlation group assignments
may have also been driven by differences in the prevalence of
HIV-specific IgG1 antibodies.
Thus, to confirm that HIV-specific IgG1 levels were the indeed the
salient features in the correlation-based clustering, we compared an-
tigen-specific IgG1 levels between array-defined groups. Again, an
unpaired t test analysis of antigen-specific IgG1 measurements be-
tween correlation-based array-defined groups resulted in significant
differences for all HIV antigens (Fig. 4B to E) (P  0.0001; the Bon-
ferroni-corrected significance threshold given multiple comparisons
is 0.0125.), while there were no significant differences between HLA-
defined groups (Fig. 4F to I). Thus, while HLA status was not associ-
ated with divergent humoral signatures or functions, antibody pro-
files were not uniform across subjects, and ECs could be classified into
two groups defined by antibody specificity and subclass responses
and associated with distinct effector function profiles.
HIV-specific IgG1 correlates with effector function. We next
sought to determine whether specific antibody features were associ-
ated with antibody effector function and determined whether there
were any correlations between individual HIV-specific antibody fea-
tures and functional data. Considering HIV-specific IgG subclass
measurements individually, correlation analyses showed significant
positive correlations between all HIV-specific IgG1 measurements
and ADCP activity and between IgG1 specific to gp41 and p24 and
ADCC activity (Fig. 5A). Representative correlation plots for gp120-
specific IgG1 levels and ADCP and RFADCC activity are provided
(Fig. 5B and C). No other relationships between antigen-specific IgG
subclasses and function were significant.
We also considered relationships between the subjects’ HIV-
specific antibody signatures and their antibody profiles more
broadly by examining the relative prevalence of each IgG sub-
class in bulk plasma. Correlation analyses showed strong pos-
itive correlations between all antigen-specific IgG1 and non-
specific plasma IgG1 levels (Fig. 5A and D). Thus, a subject’s
HIV-specific antibody signature, and HIV-specific IgG1 in par-
ticular, was associated with differences in the overall properties
of plasma IgG.
Relationships among bulk plasma IgG properties. Finally, we
examined the correlative relationships between patients’ bulk
plasma antibody profiles and antibody function. A summary of
these relationships is represented in Fig. 6. A number of relation-
ships regarding plasma IgG subclass composition were identified
(Fig. 6, green boxed region): the relative plasma compositions of
IgG1 and IgG2, IgG subclasses with divergent physiological func-
tional activities, were strongly negatively correlated; in contrast,
IgG1 and IgG3, subclasses with potent cytotoxicity, were strongly
positively correlated. These relationships suggest coordination
among subclass levels toward either a more (IgG1/3) or less (IgG2)
activated state. Whether these associations are driven genetically
or modulated by immune status is unknown.
Additionally, FcR binding among low-affinity receptors was
strongly associated, consistent with common IgG binding prefer-
ences, whereas binding to the high-affinity FcR1 receptor was
not correlated with binding to low-affinity receptors, consistent
with known differences in antibody subclass and glycospecificity
relative to FcR2A, -2B, and -3A (Fig. 6, red boxed region). As
would be expected, IgG1 levels correlate positively and IgG2 levels
correlate negatively with FcR binding, and surprisingly, despite
comprising a small fraction of total plasma antibody, IgG3 levels
were positively and significantly correlated with binding to all Fc
receptors tested (subclass composition versus FcR binding rela-
tionships are boxed in blue in Fig. 6).
FIG 3 Array-defined subject groups distinguish antibody function. Comparison of functional measurements showed that the array-defined subject groups
(blue, designated H and L) distinguish patients by phagocytic activity (A), NK cell-mediated cytotoxicity (B), and MBL (C) and FcR2a (D) binding. (E to H) No
differences in these functions are observed comparing patients based on HLA status (protective [P] and nonprotective [NP]; in green). The Bonferroni-corrected
significance threshold given multiple comparisons is 0.0125.
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FIG 4 Array-defined groups are distinguished by HIV-specific IgG1 levels. (A) A clustering analysis of patients and features based on scaled and centered
antibody subclass specificity measurements is represented by a heat map. Notably, all antigen-specific IgG1 features clustered together, with patients grouped
consistently with differences in the levels of HIV-specific IgG1 antibodies. (B to E) Closer inspection of the array-defined groups showed that groups were
differentiated by high (H) and low (L) IgG1 levels of antibodies to gp120 (B), gp140 (C), gp41 (D), and p24 (E). No difference was observed between HLA-defined
groups of ECs with (P) or without (NP) protective alleles (F to I) or among other antibody subclasses (***, P  0.0001). The Bonferroni-corrected significance
threshold given multiple comparisons is 0.0125.
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Lastly, a number of measurements made on total plasma IgG
demonstrated significant correlations with functional measure-
ments of HIV-specific antibodies (ADCP and RFADCC), though
these antibodies are assumed to represent a minor species of total
plasma IgG. Of particular note, fucosylation of plasma IgG, as
measured by AAL ELISA, was inversely correlated with RFADCC
activity. This relationship is consistent with the known ability of
afucosylated antibodies to enhance ADCC activity but, again, sur-
prising with respect to the observation that total plasma IgG ex-
hibits properties consistent with the functional activity of a small
subpopulation (2%). Additionally, plasma IgG reactivity to
MBL, a plasma protein that can initiate the complement cascade,
was associated with phagocytic activity. Furthermore, MBL dem-
onstrated strong associative relationships with plasma IgG sub-
class measurements, indicating that each subclass may exhibit in-
herent differences in ability to drive complement deposition via
this pathway. Whether such differences are driven by their diver-
gent protein backbones or differences in the glycosylation state
among subclasses is unclear.
Thus, overall, a number of relationships consistent with known
IgG-FcR biology were captured using this unbiased exploration of
correlative relationships, and consistent patterns were often observed
between total plasma IgG and the HIV-specific fraction. Whether
these results imply that preexisting differences in IgG characteristics
impact the function of HIV-specific antibodies produced by each
subject or whether the inflammatory state present during infection
drives similar modifications to both HIV-specific and total plasma
IgG remains to be determined.
DISCUSSION
ECs represent a promising opportunity to determine immuno-
phenotypic markers of protective responses to HIV infection (1).
While it has been speculated that there may be multiple mecha-
nisms by which viral suppression is mediated and there have been
many associations with nonprogression, translating these associ-
ations into a mechanistic understanding of viral control has been
remarkably challenging. At the outset of this study, we hypothe-
sized that a CD8 T cell-dependent mechanism for immune con-
trol of HIV replication in ECs with a protective HLA allele might
alter the characteristics of the humoral response. However, our
results indicate that antibody responses between ECs with and
without a protective HLA allele are not remarkably different.
Among a set of 28 measurements, the level of IgG2 antibodies to
gp41 was the only significant difference observed between the two
HLA-defined groups, providing little support for the hypothesis
that humoral immunity is potentiated in the setting of either pro-
tective or nonprotective HLA alleles.
This result has two potential explanations: either antibody re-
sponses were relatively uniform across subjects or protective HLA
alleles were not associated with divergent humoral responses. To
rule out the first explanation, we analyzed the subclass specificity
profiles of HIV-specific antibodies. Correlation-based clustering
analysis of the antibody array data grouped patients into two dis-
tinct groups, which were predictive of antibody effector function,
including ADCC and ADCP activities. Closer inspection of array-
defined groups showed that levels of HIV-specific IgG1 antibodies
were the main structural feature distinguishing array-defined
FIG 5 HIV-specific IgG1 levels correlate with enhanced effector function and elevation of total plasma IgG1. (A) Correlation coefficient plot of HIV-specific
IgG1 versus phagocytosis (ADCP), cytotoxic activity (RFADCC), and the percentage of bulk plasma IgG of the IgG1 subclass (*, P  0.05; **, P  0.01; ***, P 
0.001). (B to D) Scatterplots of gp120-specific IgG1 with ADCP (B), RFADCC (C), and plasma IgG1 levels as a percentage of total plasma IgG (D).
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FIG 6 Correlations between bulk IgG subclass measurements and functional measurements. Shown are orrelation coefficients and scatterplots of bulk plasma
IgG composition, bulk plasma IgG FcR binding, IgG fucosylation (AAL binding), IgG agalactosylation (MBL binding), ADCP and RFADCC activity, and
subject CD4 count. Strength of correlation is represented with color, with orange representing strong negative correlations and blue representing strong positive
correlations. Relationships between bulk plasma IgG subclasses are boxed in green; %IgG1 and %IgG3 showed strong positive correlation, while %IgG1 and
%IgG2 showed strong negative correlation. Relationships between FcR binding profiles are boxed in red; binding to FcR2A, FcR2B, and FcR3A showed
strong positive correlation and no relationship with the high-affinity FcR1 receptor. Relationships between bulk plasma IgG subclasses and FcR binding are
boxed in blue; %IgG3 showed strong positive correlation with binding to all FcRs despite its low serum abundance. %IgG1 showed strong correlation with
binding to FcR1, while %IgG2 showed strong negative correlation to FcR1 binding. Phagocytic activity (ADCP) was positively associated with IgG1 and IgG3
levels and binding to FcR1 and FcR2B. Cytolytic activity (RFADCC) was positively associated most strongly with binding to FcR3A and inversely with
antibody fucosylation as measured by binding to the fucose-sensitive lectin AAL (*, P  0.05; **, P  0.01; ***, P  0.001).
Lai et al.
2806 jvi.asm.org Journal of Virology
groups. That HIV-specific IgG1 antibodies positively correlate
with ADCC and ADCP activities suggests that these antibodies
may be mechanistically relevant to the differences in functional
measurements between array-defined groups. Therefore, while
there is no strong associative relationship between HLA status and
antibody responses, we demonstrate divergent antibody re-
sponses within this cohort of ECs and that these divergent re-
sponses lead to divergent antibody effector function activity.
Dissection of the antibody responses in this EC cohort yielded
other relationships that are consistent with the biology of anti-
body effector function. For example, positive correlations be-
tween IgG3 levels and Fc receptor binding were observed (Fig. 6,
blue box). This result is not surprising given that IgG3 has the
strongest affinity for all Fc receptors, but it was unexpected given
its relative rarity in plasma (less than 10% of total IgG). FcR2A,
FcR2B, and FcR3A binding were also positively correlated, re-
flecting their higher sequence and structural similarity relative to
FcR1 (Fig. 6, red box). Antibody fucosylation, as determined by
AAL binding, and FcR3A binding were correlated with ADCC
activity (Fig. 6): these results are unsurprising given the expression
of FcR3A on NK cells and its known dependence on fucose.
However, it was surprising that these properties of bulk plasma
IgG were correlated with the function of the HIV-specific subspe-
cies. Thus, several results of this study imply that global bulk IgG
cues may be representative of the composition of the antibody
compartment in a way that conserves Fc domain features across
multiple antibody specificities. Indeed, the correlations between
bulk and HIV-specific IgG1 levels observed in this study and the
correlations between the subclass profiles of antibodies to differ-
ent HIV antigens observed previously (32) are consistent with this
possibility.
Additionally, the divergence of antibody responses within the
EC patient cohort highlights the need to place these antibody ef-
fector functions in the context of viral control. First, it is not clear
why divergent antibody responses might have arisen. Answering
this question may provide fundamental insight into the signals
required to elicit antibodies with potentiated effector function via
vaccination. Second, it is unknown if these HIV-specific IgG1 an-
tibodies are involved in control of viral replication. While effector
function has correlated with nonprogression in numerous studies
and in both humans and macaques (12, 13, 20), whether this as-
sociation is causative remains to be determined.
Beyond HIV-specific IgG1, previous studies have described
some correlative relationships between IgG subclasses and disease
progression, yet there is limited consensus. Two studies from the
same French cohort linked gp41-specific IgG2 and CD4 Th1
responses with long-term nonprogression (35, 36), and Lal et al.
found an association between the absence of IgG2 antibodies to
gp41 and clinical disease (14). These results are consistent with
our observation that IgG2 antibodies to gp41 are enriched among
ECs with protective HLA alleles. However, another study high-
lighted the heterogeneity of antibody responses and reported ele-
vated IgG1 specific to p24 and gp120 and IgG3 specific to gp120 in
controllers compared to progressors. The same study also noted
an absence of indications of differential Th1 and Th2 polarization
between ECs and progressors (11). Two previous studies have
considered the role of protective HLA alleles in ECs. The first
reported that IgG2 antibodies against gag antigens were enriched
among ECs without protective alleles relative to those with HLA-
B*57 (16). This finding was not confirmed in our study, and
though we observed that levels of IgG2 antibodies against gp41
differed between controllers according to HLA status, they exhib-
ited the opposite trend and were enriched in ECs with protective
alleles. The second study found that B*57 carriers exhibited a
modest decrease in ADCC activity relative to subjects without this
allele (17). While not confirmed, this finding is consistent with the
trend observed between these subject groups in the data collected
here. Therefore, the landscape of IgG subclass responses to HIV
remains unresolved, and further study, both to link antibody pro-
files with mechanisms of antibody activity and to identify immune
signals associated with divergent humoral responses, is necessary.
While we only considered ECs in this study, our results further
highlight the heterogeneity of humoral immune responses to HIV
within ECs. Stratification of ECs, perhaps by antibody profile as
demonstrated here, may diminish confounding differences be-
tween ECs and allow for more illuminating comparisons between
subgroups of ECs and progressors to be made.
One intriguing result of this study is the correlation between
HIV-specific IgG1 and total plasma IgG1. It is plausible that sub-
jects with higher HIV-specific IgG1 levels had higher total IgG1
levels prior to infection, as genetic factors such as Gm allotypes
can be responsible for variations in baseline IgG subclass concen-
trations (37). An underlying variation in IgG subclass concentra-
tion could explain the divergence in HIV-specific subclass re-
sponse after infection, and knowledge of patients’ Gm allotypes
would rule out this possibility. Alternatively, the higher HIV-spe-
cific IgG1 response could be driven by the prevalence of HIV-
specific IgG1 antibodies or other genetic factors, Elevated IgG1
levels could, alternatively, be indicative of different levels of in-
flammatory signals in these subjects, as HIV infection is known to
drive IgG1-biased hypergammaglobulinemia. Further study is
necessary to determine the direction of causality in this correlative
relationship, which could provide a key to selective induction of
antibodies with potentiated effector function.
In conclusion, we show that the presence or absence of protec-
tive HLA alleles is not associated with strikingly divergent anti-
body responses, suggesting that potential CD8 T cell responses
driven by these alleles do not dramatically alter the characteristics
of the humoral immune response. Because some controllers ex-
perience transient viremia, longitudinal studies of the antibody
features among subjects experiencing temporary loss of viral con-
trol would be of significant interest in further determining the role
that antibody-mediated activities might play in the setting of
spontaneous control.
However, regardless of HLA status, controllers could be grouped
based on their HIV-specific antibody signatures, with HIV-specific
IgG1 acting as the main distinguishing factor. These array-defined
groups were associated with divergent antibody function in assays of
NK cell-mediated cytotoxic and monocyte-mediated phagocytic ac-
tivities. While it is unclear if these differences in antibody profiles
underpin differences in mechanisms of control or nonprogression,
our study further highlights the complexity of immune control in ECs
and supports the hypothesis that altered antibody subclass distribu-
tion may play a mechanistic role in potentiated effector function.
Because these nonneutralizing antibody activities have been associ-
ated with control, reduced viral load, nonprogression, and protection
in vaccine studies, understanding the specific features of IgGs with
potentiated effector function may be critical to vaccine development.
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